

Donepezil and memantine in moderate to severe Alzheimer's disease – The DOMINO-AD Trial

<https://neurodegenerationresearch.eu/survey/title-of-pidonepezil-and-memantine-in-moderate-to-severe-alzheimers-disease-the-domino-ad-trial/>

Title of project or programme

Title of PI Donepezil and memantine in moderate to severe Alzheimer's disease – The DOMINO-AD Trial

Principal Investigators of project/programme grant

Title	Forname	Surname	Institution	Country
Professor Robert	Howard	King's College London	UK	

Address of institution of lead PI

Institution King's College London
Street Address Strand
City London
Postcode WC2R 2LS

Country

- United Kingdom

Source of funding information

Medical Research Council

Total sum awarded (Euro)

3369926.45

Start date of award

01-12-2006

Total duration of award in months

69

The project/programme is most relevant to

- Alzheimer's disease and other dementias

Keywords

Research abstract in English

This RCT will examine efficacy of drug treatments for dementia (cholinesterase inhibitors and

memantine), singly and in combination, over 12 months, in 800 Alzheimer's disease (AD) patients who are already treated with a cholinesterase inhibitor but have declined to reach the transition point to moderate to severe disease. Primary outcome measures will be cognitive function, activities of daily living and cost effectiveness. Secondary outcome measures will include quality of life, institutionalisation and family carer burden. The Trial has been designed to answer questions about the treatment of patients who are representative of those seen in clinical practice in terms of outcomes that have relevance to patients, carers and society.

Lay Summary

In which category does this research fall?

- Clinical research